Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Остеоартрит: патогенные сигнальные пути и терапевтические мишени
2023-02-03
SCID: 54.1/at2nkzgm
Discuss with AI
NF-κB signalingWnt/β-catenin signalingosteoarthritispathological signaling pathwaystherapeutic targets
Figures from the paper
Abstract (AI)
Osteoarthritis (OA) is a chronic degenerative joint disorder that leads to disability and affects more than 500 million population worldwide. OA was believed to be caused by the wearing and tearing of articular cartilage, but it is now more commonly referred to as a chronic whole-joint disorder that is initiated with biochemical and cellular alterations in the synovial joint tissues, which leads to the histological and structural changes of the joint and ends up with the whole tissue dysfunction. Currently, there is no cure for OA, partly due to a lack of comprehensive understanding of the pathological mechanism of the initiation and progression of the disease. Therefore, a better understanding of pathological signaling pathways and key molecules involved in OA pathogenesis is crucial for therapeutic target design and drug development. In this review, we first summarize the epidemiology of OA, including its prevalence, incidence and burdens, and OA risk factors. We then focus on the roles and regulation of the pathological signaling pathways, such as Wnt/β-catenin, NF-κB, focal adhesion, HIFs, TGFβ/ΒΜP and FGF signaling pathways, and key regulators AMPK, mTOR, and RUNX2 in the onset and development of OA. In addition, the roles of factors associated with OA, including MMPs, ADAMTS/ADAMs, and PRG4, are discussed in detail. Finally, we provide updates on the current clinical therapies and clinical trials of biological treatments and drugs for OA. Research advances in basic knowledge of articular cartilage biology and OA pathogenesis will have a significant impact and translational value in developing OA therapeutic strategies.
Key Findings
1
AMPK, mTOR, RUNX2, MMPs, ADAMTS/ADAMs, and PRG4 are highlighted as key molecular regulators or factors involved in OA pathogenesis.
2
Improved understanding of articular cartilage biology, pathogenic signaling, and molecular targets is expected to support development of biological therapies and drugs for OA.
3
OA currently has no cure, partly because the mechanisms driving disease initiation and progression remain incompletely understood.
4
Osteoarthritis is characterized as a chronic whole-joint disorder initiated by biochemical and cellular alterations, rather than simple cartilage wear and tear.
5
The review identifies Wnt/β-catenin, NF-κB, focal adhesion, HIF, TGFβ/BMP, and FGF signaling pathways as central regulators of OA onset and progression.
Research Object
osteoarthritis as a chronic whole-joint disorder
Research Subject
pathogenic signaling pathways, key molecular regulators, and therapeutic targets involved in OA onset and progression
Publication Details
Publication Date
2023-02-03
Journal
Publisher
ISSN
Cited by
1414
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai8
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20172018
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee2012
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee2020
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 20152016
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee2020
The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis2020
Subchondral bone microenvironment in osteoarthritis and pain2021
Cited by6
NF-κB in biology and targeted therapy: new insights and translational implications2024
Osteoarthritis: molecular pathogenesis and potential therapeutic options2026
Osteoarthritis: Epidemiology, Pathogenesis, and Treatment2026
Pathogenesis and therapeutic strategies of osteoarthritis: roles of immune cells, inflammatory mediators, and pathogenic signaling pathways2026
Chondrocyte inflammatory-immune responses in osteoarthritis: From pathogenesis to therapeutic intervention2026
Pathogenesis of Osteoarthritis: Mechanisms of Action of Disulfidptosis and Targeted Therapeutic Strategies2026